Posted by Michael Wonder on 29 Mar 2022
Novo Nordisk receives FDA approval of higher-dose Ozempic 2 mg providing increased glycemic control for adults with type 2 diabetes
28 March 2022 - Ozempic demonstrated 2.1% blood sugar reduction and also weight loss in adults with type 2 diabetes with new 2 mg dose.
Novo Nordisk today announced that the US FDA has approved a 2 mg dose of Ozempic (semaglutide) injection, a once weekly glucagon-like peptide-1 analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.
